Multimodal glyco-lipid-EBVDNA signature prognostic model for individualized risk stratification of locally advanced nasopharyngeal carcinoma
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-026-07781-x ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Jiayu Zhou und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Cli…. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Herpesvirus 4, Human, DNA, Viral, Nasopharyngeal Neoplasms. Die Arbeit nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: To develop and validate a novel risk stratification model for locally advanced nasopharyngeal carcinoma (LA-NPC) based on the "glyco-lipid-viral" axis, addressing the limitations of traditional TNM staging and single-modality biomarkers. METHODS: A total of 486 LA-NPC patients were retrospectively enrolled, with a metabolomics subcohort (n = 121) selected. PET/CT-derived glycolytic parameters (MTV, TLG), serum lipid biomarkers, and pretreatment EBV DNA were integrated via recursive partitioning analysis (RPA) to construct the model. Its performance was compared with TNM staging and single-modality markers. RESULTS: A multimodal model was built via RPA in 121 LA-NPC patients, using Lipsig-Score (lipid metabolite signature score), naso_MTV (PET/CT), and pretreatment EBV DNA. Three risk groups were defined: low-risk (Lipsig-Score < 0.0127 + EBV DNA < 500 copies/mL), intermediate-risk (Lipsig-Score < 0.0127 + EBV DNA ≥ 500 copies/mL, or Lipsig-Score ≥ 0.0127 + naso_MTV < 5.5), and high-risk (Lipsig-Score ≥ 0.0127 + naso_MTV ≥ 5.5). Kaplan–Meier analysis showed significant differences in PFS (log-rank P < 0.0001) and OS (log-rank P < 0.001) among groups, with the model outperforming TNM staging and single-modal markers. CONCLUSION: The integrated model captures LA-NPC’s multi-dimensional biology, enabling precise risk stratification and providing a reliable basis for individualized treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center…
- Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China.
- Department of Nuclear Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China.
- Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China. xiawx@sysucc.org.cn.
ORCID-Profile: Weixiong Xia
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, J., Hua, Y., Zhang, C., Liu, Q., Deng, Y., Kuang, Y., Lu, J., Wang, M., Gong, J., Guo, X., Lv, X., Yang, Z., & Xia, W. (2026). Multimodal glyco-lipid-EBVDNA signature prognostic model for individualized risk stratification of locally advanced nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07781-x
Vancouver
Zhou J, Hua Y, Zhang C, Liu Q, Deng Y, Kuang Y, et al. Multimodal glyco-lipid-EBVDNA signature prognostic model for individualized risk stratification of locally advanced nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07781-x
BibTeX
@article{Zhou2026,
author = {Zhou, Jiayu and Hua, Yuchen and Zhang, Chuanrun and Liu, Qin and Deng, Ying and Kuang, Yuwen and Lu, Jiahuan and Wang, Mengwen and Gong, Jie and Guo, Xiang and Lv, Xing and Yang, Zhenchong and Xia, Weixiong},
title = {Multimodal glyco-lipid-EBVDNA signature prognostic model for individualized risk stratification of locally advanced nasopharyngeal carcinoma},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-026-07781-x}
}
EUVIMED